FY27 revenue run-rate target of $2 Billion. Al adoption expected to accelerate across clients. EBIT margin aspiration of 16-17%. Continued growth across BFSI, Healthcare & Technology.
Double-digit volume growth expected to continue. Premiumisation supporting revenue growth. New capacity additions to support demand. Distribution expansion to drive market share gains.
Strong earnings visibility supported by premiumisation. Homes segment emerging as second growth engine. Potential tariff hikes may support ARPU growth. Improving margins & deleveraging strengthening profitability.
Early double-digit revenue growth expected in FY27. Continued momentum in Animal Nutrition business. Recovery expected across crop care & Astec businesses. Improving profitability and capital efficiency.
Strong revenue visibility from record order book. Margin expansion supported by operating leverage. Capacity expansion supporting future growth. Export opportunities strengthening global presence.
Bed occupancy improved from ~55% in FY21 to ~68% in FY25. Strong demand for high-acuity CONGO-T specialties. Average revenue per inpatient rising with better case mix.
Order Book: Rs 63,287 Cr. FY26 Inflows: Rs 19,456 Cr. Core Segments: ~70% of order book. Order book doubled in 4 years. Domestic 74% | International 26%.